The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

President Donald Trump announced major GLP-1 drug price cuts with Eli Lilly and Novo Nordisk, reducing costs for Ozempic and Wegovy.

Trump launches "TrumpRx" program to cut prices of Wegovy and Zepbound, making weight-loss drugs more affordable for Americans ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...